Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

Barchart

Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices

The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies

The Independent UK

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

MarketBeat

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable

IN FULL

The Independent UK

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

Barchart

US approves new oral weight-loss pill developed by Eli Lilly

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

The Guardian - US

Read news from The Economist, FT, and more,
with one subscription

Foundayo: All you need to know about the newly approved weight-loss pill

The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times

The Independent UK

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Barchart

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

Euronews

Mounjaro maker wants NHS drug price rises in return for more investment in UK

US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministers

The Guardian - UK

The FDA just approved triple the previous maximum dose of Wegovy

People taking ‘Wegovy HD’ lost an average of 21 percent of their body weight after 72 weeks

The Independent UK

Could a new type of weight-loss pill shake up the market? Here’s what to know about orforglipron

A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.

The Conversation

Members of Congress Bought These 5 Stocks—Should You?

Five stocks recently traded by members of Congress—from AI defense to GLP-1 leaders—could offer clues for investors building their watchlists

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

MarketBeat

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

The Independent UK

‘I bought weight loss jabs on social media – this is why I regret it’

Doctor warns buying weight loss drugs from illegitimate sources like social media could be ‘life-threatening’

MarketBeat

The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Fortune

Tech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems

Eli Lilly CEO David Ricks said AI can’t quite solve complex scientific problems without advanced data.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Euronews

New oral pill beats previous alternatives and shows 8% weight loss in clinical trials

Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives.

The Guardian - UK

New GLP-1 pill helps patients lose up to 8% of body weight, trial shows

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs

Barchart

Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

The Independent UK

Asian shares are mixed after heavy selling of potential AI losers hits Wall Street

Shares are mixed in Asia after U.S. stocks slumped on heavy selling of shares in companies that could be losers in the artificial-intelligence boom

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Cancer

22,791 stories

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.